Biotech stock Alkermes plunges 20% after FDA refuses to review its depression treatment
April 02, 2018 at 08:32 AM EDT
Alkermes announced Monday it received a "Refusal to File" letter from the U.S. Food and Drug Administration regarding the company's application for a new drug called ALKS 5461.
